Abstract
No abstract available.
Highlights
We read with interest the response by Ingram et al to our report on transfusion-acquired human T-lymphotropic virus 1 (HTLV-1) infection and disease.[1]
None of the more than 200 black African patients seen with HTLV-1associated myelopathy/tropical spastic paraparesis (HAM/TSP) provided a history of receiving any blood products
Quoting Hewitt et al, the authors indicated that the prevalence of transfusion transmission after leukoreduction was less than 1%
Summary
We read with interest the response by Ingram et al to our report on transfusion-acquired human T-lymphotropic virus 1 (HTLV-1) infection and disease.[1]. Routine testing for HTLV-1 in any country with a prevalence of ≤ 1:100 000 positivity is of questionable value. None of the more than 200 black African patients seen with HTLV-1associated myelopathy/tropical spastic paraparesis (HAM/TSP) provided a history of receiving any blood products. Quoting Hewitt et al, the authors indicated that the prevalence of transfusion transmission after leukoreduction was less than 1%.4 the figure given in the paper was 3.7%.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call